Oxford Global, Hyatt Regency Boston, One Avenue de Lafayette, Boston, Massachusetts, United States, 02111
07 - 08 April 2020
350+ end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical & biotech companies. 3 outstanding programmes bringing together Europe’s key genomics experts in Next Generation Sequencing, Single Cell Analysis, Genome Editing. 80+ case studies, solution & technology presentations & 2 interactive workshops over the 2 days. 07 April 2019 – Day One - Genome Editing Technologies & Techniques
- Drug Discovery & Development Applications in In Vivo Therapeutics
08 April 2019 – Day Two - Drug Discovery & Development – Target Identification and Validation
- Non-Human Models in Diagnostics & Therapeutics
View Agenda: http://bit.ly/2rLMzeL 2020 Live Webinar Chemically-Modified Polynucleotides for Inhibiting, Expressing and Repairing Nucleic Acids: Then & Now Presented by Tod Woolf, Founder & CEO, ETAGEN Pharma, Inc. Tuesday, 10 March 2020 | 03:30 PM GMT Register: https://bit.ly/2QvO7Us
|
|
|
Invited Speakers:
|
|
George Church, Professor of Genetics, Health Sciences and Technology, Wyss Institute at Harvard University Tod Woolf, Founder and Chief Executive Officer, ETAGEN Pharma, Inc. Svetlana Belyanskaya, Scientific Leader, Encoded Library Technologies, GlaxoSmithKline Salil Desai, Chief Executive Officer, PhenomYX Luhan Yang, Co-Founder and Chief Scientific Officer, eGenesis Nadeem Sarwar, Founder & President, Eisai Center for Genetics Guided Dementia Discovery, Eisai John Reidhaar-Olson, Senior Director, Pfizer Oleg Iartchouk, Director, Genomics and Next-Generation Sequencing, Novartis
|
|